Singulair - Patient Info

Montelukast sodium

• Singulair - Drug Description
• Singulair - Side Effects & Drug Interactions
• Singulair - Warnings & Precautions
• Singulair - Clinical Pharmacology
• Singulair - Overdosage & Contraindications
• Singulair - Indications & Dosage

Information for Patients

° Patients should be advised to take SINGULAIR daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physicians if their asthma is not well controlled.

° Patients should be advised that oral SINGULAIR is not for the treatment of acute asthma attacks. They should have appropriate short-acting inhaled -agonist medication available to treat asthma exacerbations.

° Patients should be advised that, while using SINGULAIR, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-hour period are needed.

° Patients receiving SINGULAIR should be instructed not to decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.

° Patients who have exacerbations of asthma after exercise should be instructed to continue to use their usual regimen of inhaled -agonists as prophylaxis unless otherwise instructed by their physician. All patients should have available for rescue a short-acting inhaled -agonist.

° Patients with known aspirin sensitivity should be advised to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR.

Chewable Tablets

° Phenylketonurics: Phenylketonuric patients should be informed that the 4-mg and 5-mg chewable tablets contain phenylalanine (a component of aspartame), 0.674 and 0.842 mg per 4-mg and 5-mg chewable tablet, respectively.